GlassScriptPhysician profile
Jeffrey D Rubinstein
NPI 1417953399
$22,178.66
in general payments reported to CMS, 2019-2025
30 companies · $921 in 2025
The $921 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,347 · 2020: $8,019 · 2021: $1,216 · 2022: $2,697 · 2023: $1,696 · 2024: $1,283 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,899.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $8,623.43 | 2019-2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder |
| Abbott Laboratories | $2,694.96 | 2019-2025 | Diamondback Coronary, Mitraclip, Optis |
| Medtronic Vascular, INC. | $2,324.37 | 2019-2020 | |
| Shockwave Medical, INC | $2,204.54 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $2,080.40 | 2019-2025 | Avvigo Guidance System, Rotablator Rotational Atherectomy System Console Kit, Synergy |
| Philips North America LLC | $1,788.86 | 2019-2024 | (9266) Elca |
| Abiomed | $547.40 | 2019-2025 | |
| Edwards Lifesciences Corporation | $313.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $230.28 | 2021-2024 | Verquvo |
| Pfizer INC. | $225.95 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $180.07 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $167.42 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $121.97 | 2023-2024 | |
| Cardiovascular Systems INC. | $98.78 | 2019-2023 | Diamondback Coronary |
| E.R. Squibb & Sons, L.L.C. | $69.96 | 2024 | Camzyos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $63.60 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $56.17 | 2021 | |
| Esperion Therapeutics, INC. | $46.54 | 2023-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $39.98 | 2024 | |
| Novo Nordisk INC | $39.61 | 2024 | Wegovy, Ozempic, Rybelsus |
| Asahi Intecc USA, INC. | $38.25 | 2019 | |
| Amgen INC. | $36.41 | 2019-2023 | Repatha |
| Heartflow, INC. | $33.87 | 2023-2024 | Ffrct |
| Medtronic, INC. | $26.26 | 2022-2023 | Azure Xt Dr Mri Surescan |
| Impulse Dynamics (USA) INC. | $26.14 | 2022 | |
| Baxter Healthcare | $24.92 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $22.48 | 2023 | Inpefa |
| Ge Healthcare | $21.72 | 2019 | |
| Scpharmaceuticals INC. | $16.34 | 2023 | |
| Daiichi Sankyo INC. | $14.43 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.